Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by NeXstar Pharmaceuticals and licensed in 2000 to EyeTech Pharmaceuticals now OSI Pharmaceuticals for late stage development and marketing in the United States. Outside the US pegaptanib is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
thumbnail
ATC prefix
S01
ATC suffix
LA03
CAS number
222716-86-1
DrugBank
DB04895
FDA UNII code
2H1PA8H1EN
IUPAC name
RNA ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-Am-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'→3')-dT) 5'-ester with αα'-[412-dioxo-6[[[5-(phosphoonoxy)pentyl]amino]carbonyl]-313-dioxa-511-diaza-115-pentadecanediyl]bis[ω-methoxypoly(oxy-12-ethanediyl)] sodium salt
This page contains content from the copyrighted Wikipedia article "Pegaptanib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
